Loading…
Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study
Thirteen patients with myasthenia gravis, unresponsive to prednisone and cyclosporin after thymectomy, received KF506 (tacrolimus) for 12 months, at starting doses of 0.1 mg/kg per day b.i.d. and then adjusted to achieve plasma concentrations between 7 and 8 ng/mL. The doses of prednisone were progr...
Saved in:
| Published in: | Clinical neurology and neurosurgery 2005-04, Vol.107 (3), p.187-190 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c490t-d402da44ea100310696f1d70c4ee4fbdfcdd009bca0c4cc625271a5887c9cc5f3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c490t-d402da44ea100310696f1d70c4ee4fbdfcdd009bca0c4cc625271a5887c9cc5f3 |
| container_end_page | 190 |
| container_issue | 3 |
| container_start_page | 187 |
| container_title | Clinical neurology and neurosurgery |
| container_volume | 107 |
| creator | Ponseti, José M. Azem, Jamal Fort, José M. Codina, Agustín Montoro, J. Bruno Armengol, Manuel |
| description | Thirteen patients with myasthenia gravis, unresponsive to prednisone and cyclosporin after thymectomy, received KF506 (tacrolimus) for 12 months, at starting doses of 0.1
mg/kg per day b.i.d. and then adjusted to achieve plasma concentrations between 7 and 8
ng/mL. The doses of prednisone were progressively reduced and finally discontinued. Anti-acetylcholine antibodies and myasthenia gravis score for disease severity decreased significantly and muscular strength increased by 37%. All patients achieved pharmacological remission, 11 were asymptomatic and two had minimal weakness of eyelid closure. Tacrolimus was well tolerated and appears a suitable approach after unsuccessful treatment with conventional immunosuppressants in patients with disabling myasthenia. |
| doi_str_mv | 10.1016/j.clineuro.2004.07.013 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67729492</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0303846704001143</els_id><sourcerecordid>2731746741</sourcerecordid><originalsourceid>FETCH-LOGICAL-c490t-d402da44ea100310696f1d70c4ee4fbdfcdd009bca0c4cc625271a5887c9cc5f3</originalsourceid><addsrcrecordid>eNqF0dGK1TAQBuAiintcfYUlIIqCrUmaJq1X6uKquOCNXoecZKI5pEk3aVf6FL6yKefIgjdeBcI3k8z8VXVBcEMw4a8PjfYuwJJiQzFmDRYNJu29akd6QWs-8P5-tcMtbuuecXFWPcr5gDFuW94_rM5I19OWi3ZX_X4PAaybM4oWXX3pMEcvZqVT9G5c8ktkY0IJsjOL8q-QXrWPeYrJhRqpYNCUwASXY4B6U3lWYUbjqvL8E4JT6EdSty6_QRtYQaXSz_v4q16m7T0VUJwg1F7twaM8L2Z9XD2wymd4cjrPq-9XH75dfqqvv378fPnuutZswHNtGKZGMQaKlKEILgNbYgTWDIDZvbHaGIyHvVblSmtOOyqI6vpe6EHrzrbn1fNj3ynFmwXyLEeXNXivAsQlSy4EHdhAC3z6DzzEJYXyN0lwS0VHy86K4kdVNpdzAiun5EaV1oLkFpg8yL-ByS0wiYUsgZXCi1P7ZT-CuSs7JVTAsxNQWStvkwra5TvH-cDEMBT39uigbO3WQZJZOwgajEugZ2mi-99f_gDcH7lE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1032752506</pqid></control><display><type>article</type><title>Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Ponseti, José M. ; Azem, Jamal ; Fort, José M. ; Codina, Agustín ; Montoro, J. Bruno ; Armengol, Manuel</creator><creatorcontrib>Ponseti, José M. ; Azem, Jamal ; Fort, José M. ; Codina, Agustín ; Montoro, J. Bruno ; Armengol, Manuel</creatorcontrib><description>Thirteen patients with myasthenia gravis, unresponsive to prednisone and cyclosporin after thymectomy, received KF506 (tacrolimus) for 12 months, at starting doses of 0.1
mg/kg per day b.i.d. and then adjusted to achieve plasma concentrations between 7 and 8
ng/mL. The doses of prednisone were progressively reduced and finally discontinued. Anti-acetylcholine antibodies and myasthenia gravis score for disease severity decreased significantly and muscular strength increased by 37%. All patients achieved pharmacological remission, 11 were asymptomatic and two had minimal weakness of eyelid closure. Tacrolimus was well tolerated and appears a suitable approach after unsuccessful treatment with conventional immunosuppressants in patients with disabling myasthenia.</description><identifier>ISSN: 0303-8467</identifier><identifier>EISSN: 1872-6968</identifier><identifier>DOI: 10.1016/j.clineuro.2004.07.013</identifier><identifier>PMID: 15823673</identifier><identifier>CODEN: CNNSBV</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Cyclosporin ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Follow-Up Studies ; Glucocorticoids - administration & dosage ; Humans ; Immunosuppressive Agents - administration & dosage ; Immunosuppressive Agents - blood ; Male ; Medical sciences ; Middle Aged ; Myasthenia gravis ; Myasthenia Gravis - blood ; Myasthenia Gravis - drug therapy ; Neurology ; Neurosurgery ; Prednisolone - administration & dosage ; Prednisone ; Prospective Studies ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Tacrolimus ; Tacrolimus - administration & dosage ; Tacrolimus - blood ; Treatment Outcome</subject><ispartof>Clinical neurology and neurosurgery, 2005-04, Vol.107 (3), p.187-190</ispartof><rights>2004 Elsevier B.V.</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c490t-d402da44ea100310696f1d70c4ee4fbdfcdd009bca0c4cc625271a5887c9cc5f3</citedby><cites>FETCH-LOGICAL-c490t-d402da44ea100310696f1d70c4ee4fbdfcdd009bca0c4cc625271a5887c9cc5f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16694799$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15823673$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ponseti, José M.</creatorcontrib><creatorcontrib>Azem, Jamal</creatorcontrib><creatorcontrib>Fort, José M.</creatorcontrib><creatorcontrib>Codina, Agustín</creatorcontrib><creatorcontrib>Montoro, J. Bruno</creatorcontrib><creatorcontrib>Armengol, Manuel</creatorcontrib><title>Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study</title><title>Clinical neurology and neurosurgery</title><addtitle>Clin Neurol Neurosurg</addtitle><description>Thirteen patients with myasthenia gravis, unresponsive to prednisone and cyclosporin after thymectomy, received KF506 (tacrolimus) for 12 months, at starting doses of 0.1
mg/kg per day b.i.d. and then adjusted to achieve plasma concentrations between 7 and 8
ng/mL. The doses of prednisone were progressively reduced and finally discontinued. Anti-acetylcholine antibodies and myasthenia gravis score for disease severity decreased significantly and muscular strength increased by 37%. All patients achieved pharmacological remission, 11 were asymptomatic and two had minimal weakness of eyelid closure. Tacrolimus was well tolerated and appears a suitable approach after unsuccessful treatment with conventional immunosuppressants in patients with disabling myasthenia.</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Cyclosporin</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Glucocorticoids - administration & dosage</subject><subject>Humans</subject><subject>Immunosuppressive Agents - administration & dosage</subject><subject>Immunosuppressive Agents - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Myasthenia gravis</subject><subject>Myasthenia Gravis - blood</subject><subject>Myasthenia Gravis - drug therapy</subject><subject>Neurology</subject><subject>Neurosurgery</subject><subject>Prednisolone - administration & dosage</subject><subject>Prednisone</subject><subject>Prospective Studies</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Tacrolimus</subject><subject>Tacrolimus - administration & dosage</subject><subject>Tacrolimus - blood</subject><subject>Treatment Outcome</subject><issn>0303-8467</issn><issn>1872-6968</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNqF0dGK1TAQBuAiintcfYUlIIqCrUmaJq1X6uKquOCNXoecZKI5pEk3aVf6FL6yKefIgjdeBcI3k8z8VXVBcEMw4a8PjfYuwJJiQzFmDRYNJu29akd6QWs-8P5-tcMtbuuecXFWPcr5gDFuW94_rM5I19OWi3ZX_X4PAaybM4oWXX3pMEcvZqVT9G5c8ktkY0IJsjOL8q-QXrWPeYrJhRqpYNCUwASXY4B6U3lWYUbjqvL8E4JT6EdSty6_QRtYQaXSz_v4q16m7T0VUJwg1F7twaM8L2Z9XD2wymd4cjrPq-9XH75dfqqvv378fPnuutZswHNtGKZGMQaKlKEILgNbYgTWDIDZvbHaGIyHvVblSmtOOyqI6vpe6EHrzrbn1fNj3ynFmwXyLEeXNXivAsQlSy4EHdhAC3z6DzzEJYXyN0lwS0VHy86K4kdVNpdzAiun5EaV1oLkFpg8yL-ByS0wiYUsgZXCi1P7ZT-CuSs7JVTAsxNQWStvkwra5TvH-cDEMBT39uigbO3WQZJZOwgajEugZ2mi-99f_gDcH7lE</recordid><startdate>20050401</startdate><enddate>20050401</enddate><creator>Ponseti, José M.</creator><creator>Azem, Jamal</creator><creator>Fort, José M.</creator><creator>Codina, Agustín</creator><creator>Montoro, J. Bruno</creator><creator>Armengol, Manuel</creator><general>Elsevier B.V</general><general>Elsevier Science</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20050401</creationdate><title>Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study</title><author>Ponseti, José M. ; Azem, Jamal ; Fort, José M. ; Codina, Agustín ; Montoro, J. Bruno ; Armengol, Manuel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c490t-d402da44ea100310696f1d70c4ee4fbdfcdd009bca0c4cc625271a5887c9cc5f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Cyclosporin</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Glucocorticoids - administration & dosage</topic><topic>Humans</topic><topic>Immunosuppressive Agents - administration & dosage</topic><topic>Immunosuppressive Agents - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Myasthenia gravis</topic><topic>Myasthenia Gravis - blood</topic><topic>Myasthenia Gravis - drug therapy</topic><topic>Neurology</topic><topic>Neurosurgery</topic><topic>Prednisolone - administration & dosage</topic><topic>Prednisone</topic><topic>Prospective Studies</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Tacrolimus</topic><topic>Tacrolimus - administration & dosage</topic><topic>Tacrolimus - blood</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ponseti, José M.</creatorcontrib><creatorcontrib>Azem, Jamal</creatorcontrib><creatorcontrib>Fort, José M.</creatorcontrib><creatorcontrib>Codina, Agustín</creatorcontrib><creatorcontrib>Montoro, J. Bruno</creatorcontrib><creatorcontrib>Armengol, Manuel</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Psychology Database</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical neurology and neurosurgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ponseti, José M.</au><au>Azem, Jamal</au><au>Fort, José M.</au><au>Codina, Agustín</au><au>Montoro, J. Bruno</au><au>Armengol, Manuel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study</atitle><jtitle>Clinical neurology and neurosurgery</jtitle><addtitle>Clin Neurol Neurosurg</addtitle><date>2005-04-01</date><risdate>2005</risdate><volume>107</volume><issue>3</issue><spage>187</spage><epage>190</epage><pages>187-190</pages><issn>0303-8467</issn><eissn>1872-6968</eissn><coden>CNNSBV</coden><abstract>Thirteen patients with myasthenia gravis, unresponsive to prednisone and cyclosporin after thymectomy, received KF506 (tacrolimus) for 12 months, at starting doses of 0.1
mg/kg per day b.i.d. and then adjusted to achieve plasma concentrations between 7 and 8
ng/mL. The doses of prednisone were progressively reduced and finally discontinued. Anti-acetylcholine antibodies and myasthenia gravis score for disease severity decreased significantly and muscular strength increased by 37%. All patients achieved pharmacological remission, 11 were asymptomatic and two had minimal weakness of eyelid closure. Tacrolimus was well tolerated and appears a suitable approach after unsuccessful treatment with conventional immunosuppressants in patients with disabling myasthenia.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>15823673</pmid><doi>10.1016/j.clineuro.2004.07.013</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0303-8467 |
| ispartof | Clinical neurology and neurosurgery, 2005-04, Vol.107 (3), p.187-190 |
| issn | 0303-8467 1872-6968 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67729492 |
| source | ScienceDirect Freedom Collection 2022-2024 |
| subjects | Adult Aged Biological and medical sciences Cyclosporin Dose-Response Relationship, Drug Drug Administration Schedule Female Follow-Up Studies Glucocorticoids - administration & dosage Humans Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - blood Male Medical sciences Middle Aged Myasthenia gravis Myasthenia Gravis - blood Myasthenia Gravis - drug therapy Neurology Neurosurgery Prednisolone - administration & dosage Prednisone Prospective Studies Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Tacrolimus Tacrolimus - administration & dosage Tacrolimus - blood Treatment Outcome |
| title | Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T02%3A11%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Benefits%20of%20FK506%20(tacrolimus)%20for%20residual,%20cyclosporin-%20and%20prednisone-resistant%20myasthenia%20gravis:%20one-year%20follow-up%20of%20an%20open-label%20study&rft.jtitle=Clinical%20neurology%20and%20neurosurgery&rft.au=Ponseti,%20Jos%C3%A9%20M.&rft.date=2005-04-01&rft.volume=107&rft.issue=3&rft.spage=187&rft.epage=190&rft.pages=187-190&rft.issn=0303-8467&rft.eissn=1872-6968&rft.coden=CNNSBV&rft_id=info:doi/10.1016/j.clineuro.2004.07.013&rft_dat=%3Cproquest_cross%3E2731746741%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c490t-d402da44ea100310696f1d70c4ee4fbdfcdd009bca0c4cc625271a5887c9cc5f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1032752506&rft_id=info:pmid/15823673&rfr_iscdi=true |